Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 26, 2024 08:00 ET | Source: Healis Therapeutics

Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates of Harvard Medical School to advance clinical-stage neuroscience research

The collaboration will focus on Healis’ clinical program studying the safety and efficacy of CKDB-501A, a BoNT/A neuromodulator, for neuropsychiatry.
February 27, 2024 08:00 ET | Source: Healis Therapeutics

Healis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea

CKDB-501A, a novel BoNT/A neuromodulator protein, completed a Phase 3 trial to investigate the efficacy and safety in treating the glabella.
February 12, 2024 08:00 ET | Source: Healis Therapeutics

Healis selected to present at key biotechnology and neuroscience investor conferences in Amsterdam, New York, and San Diego

Healis' clinical program developing BoNT/A neuromodulator proteins has the potential to transform care for over 280 million patients with depression.
January 02, 2024 08:00 ET | Source: Healis Therapeutics

Healis Therapeutics Announces Supply Agreement with CKD Bio to develop CKDB-501 for neuropsychiatric indications

NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, today announced it has entered into a supply agreement with CKD Bio Corporation...
December 05, 2023 08:00 ET | Source: Healis Therapeutics

Healis Therapeutics selected to speak on opening day of 2024 Biotech Showcase in San Francisco

Healis Co-Founders Sebastian De Beurs and Dr. Eric Finzi will be presenting on the company's neurotherapeutics pipeline and clinical development.